ImageneBio (IMA) Competitors

ImageneBio logo
$3.81 -0.09 (-2.31%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 -0.04 (-1.18%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IMA vs. SION, HUMA, INO, TARA, and AKBA

Should you buy ImageneBio stock or one of its competitors? ImageneBio's main competitors and comparable companies include Sionna Therapeutics (SION), Humacyte (HUMA), Inovio Pharmaceuticals (INO), Protara Therapeutics (TARA), and Akebia Therapeutics (AKBA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImageneBio compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

ImageneBio's return on equity of -32.90% beat Sionna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sionna TherapeuticsN/A -39.78% -37.21%
ImageneBio N/A -32.90%-29.66%

75.0% of ImageneBio shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ImageneBio has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sionna TherapeuticsN/AN/A-$75.27M-$2.44N/A
ImageneBio$800K60.74-$45.35M-$4.58N/A

Sionna Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, ImageneBio had 9 more articles in the media than Sionna Therapeutics. MarketBeat recorded 10 mentions for ImageneBio and 1 mentions for Sionna Therapeutics. ImageneBio's average media sentiment score of 1.21 beat Sionna Therapeutics' score of -0.30 indicating that ImageneBio is being referred to more favorably in the news media.

Company Overall Sentiment
Sionna Therapeutics Neutral
ImageneBio Positive

Sionna Therapeutics presently has a consensus price target of $42.33, indicating a potential upside of 1,278.94%. ImageneBio has a consensus price target of $28.00, indicating a potential upside of 617.95%. Given Sionna Therapeutics' higher probable upside, equities analysts plainly believe Sionna Therapeutics is more favorable than ImageneBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sionna Therapeutics
1 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00

Summary

ImageneBio beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does ImageneBio compare to Humacyte?

Humacyte (NASDAQ:HUMA) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Humacyte has higher revenue and earnings than ImageneBio. Humacyte is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humacyte$2.04M68.22-$40.83M-$0.44N/A
ImageneBio$800K60.74-$45.35M-$4.58N/A

In the previous week, Humacyte had 12 more articles in the media than ImageneBio. MarketBeat recorded 22 mentions for Humacyte and 10 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.21 beat Humacyte's score of 0.28 indicating that ImageneBio is being referred to more favorably in the news media.

Company Overall Sentiment
Humacyte Neutral
ImageneBio Positive

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Humacyte has a beta of 2.64, meaning that its stock price is 164% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

ImageneBio has a net margin of 0.00% compared to Humacyte's net margin of -3,955.05%. ImageneBio's return on equity of -32.90% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Humacyte-3,955.05% -612.88% -80.03%
ImageneBio N/A -32.90%-29.66%

Humacyte currently has a consensus price target of $4.48, indicating a potential upside of 794.46%. ImageneBio has a consensus price target of $28.00, indicating a potential upside of 617.95%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Humacyte is more favorable than ImageneBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00

Summary

Humacyte beats ImageneBio on 10 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Inovio Pharmaceuticals?

ImageneBio (NASDAQ:IMA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

ImageneBio has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImageneBio$800K60.74-$45.35M-$4.58N/A
Inovio Pharmaceuticals$60K2,993.22-$84.95M-$0.54N/A

ImageneBio presently has a consensus target price of $28.00, indicating a potential upside of 617.95%. Inovio Pharmaceuticals has a consensus target price of $6.33, indicating a potential upside of 288.55%. Given ImageneBio's higher probable upside, research analysts plainly believe ImageneBio is more favorable than Inovio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00
Inovio Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

ImageneBio has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

ImageneBio's return on equity of -32.90% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImageneBioN/A -32.90% -29.66%
Inovio Pharmaceuticals N/A -28,886.30%-75.67%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals had 11 more articles in the media than ImageneBio. MarketBeat recorded 21 mentions for Inovio Pharmaceuticals and 10 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.21 beat Inovio Pharmaceuticals' score of 0.34 indicating that ImageneBio is being referred to more favorably in the media.

Company Overall Sentiment
ImageneBio Positive
Inovio Pharmaceuticals Neutral

Summary

ImageneBio beats Inovio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Protara Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 1,031.47%. ImageneBio has a consensus target price of $28.00, indicating a potential upside of 617.95%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protara Therapeutics is more favorable than ImageneBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ImageneBio had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for ImageneBio and 6 mentions for Protara Therapeutics. ImageneBio's average media sentiment score of 1.21 beat Protara Therapeutics' score of 0.95 indicating that ImageneBio is being referred to more favorably in the news media.

Company Overall Sentiment
Protara Therapeutics Positive
ImageneBio Positive

ImageneBio has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A
ImageneBio$800K60.74-$45.35M-$4.58N/A

ImageneBio's return on equity of -32.90% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -46.15% -42.75%
ImageneBio N/A -32.90%-29.66%

Summary

ImageneBio beats Protara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does ImageneBio compare to Akebia Therapeutics?

ImageneBio (NASDAQ:IMA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

ImageneBio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -22.60%. ImageneBio's return on equity of -32.90% beat Akebia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImageneBioN/A -32.90% -29.66%
Akebia Therapeutics -22.60%-156.59%-11.53%

ImageneBio has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than ImageneBio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImageneBio$800K60.74-$45.35M-$4.58N/A
Akebia Therapeutics$236.20M0.47-$5.34M-$0.16N/A

In the previous week, ImageneBio had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 10 mentions for ImageneBio and 9 mentions for Akebia Therapeutics. ImageneBio's average media sentiment score of 1.21 beat Akebia Therapeutics' score of -0.19 indicating that ImageneBio is being referred to more favorably in the media.

Company Overall Sentiment
ImageneBio Positive
Akebia Therapeutics Neutral

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImageneBio currently has a consensus price target of $28.00, suggesting a potential upside of 617.95%. Akebia Therapeutics has a consensus price target of $3.50, suggesting a potential upside of 774.13%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than ImageneBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00
Akebia Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

ImageneBio and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMA vs. The Competition

MetricImageneBioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$47.47M$3.97B$7.60B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-0.8324.6233.5830.13
Price / Sales59.3415.438.255.59
Price / CashN/A22.9521.0121.90
Price / Book0.374.164.443.72
Net Income-$45.35M-$24.10M$3.50B$393.88M
7 Day Performance2.42%-8.44%-6.53%-6.07%
1 Month Performance-5.69%-6.54%-4.93%-7.38%
1 Year Performance-50.07%-6.71%-1.73%-7.48%

ImageneBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMA
ImageneBio
3.2945 of 5 stars
$3.81
-2.3%
$28.00
+634.9%
-49.4%$47.47M$800KN/A18
SION
Sionna Therapeutics
1.9053 of 5 stars
$3.70
flat
$42.33
+1,044.1%
-92.3%$167.28MN/AN/A59
HUMA
Humacyte
3.2907 of 5 stars
$0.59
+0.3%
$4.98
+741.4%
-55.7%$164.37M$2.04MN/A184
INO
Inovio Pharmaceuticals
3.0769 of 5 stars
$1.48
+1.7%
$6.33
+329.4%
-17.7%$162.52MN/AN/A112
TARA
Protara Therapeutics
2.8936 of 5 stars
$2.63
+8.2%
$26.25
+898.1%
-58.3%$161.93MN/AN/A51

Related Companies and Tools


This page (NASDAQ:IMA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners